Therapeutic effect of a new posterior chamber intraocular lens implantation for high myopia with low astigmatism

AIM: To observe the efficacy and safety of a new posterior chamber intraocular lens(ICMO V4c)implantation in patients with high myopia and low astigmatism and to provide reference for the clinical diagnosis and treatment of these patients. METHODS: The study was to analyze the clinical data of patients with high myopia who underwent ICMO V4c implantation with low degree of astigmatism in our hospital from January 2015 to December 2016. The patients were followed up for 1, 3 and 6mo after operation. The items we analyzed including preoperative and postoperative uncorrected visual acuity(UCVA)and best corrected visual acuity(BCVA), diopter, spherical and cylinder equivalent, and manifest refraction spherical equivalent(MRSE), intraocular pressure(IOP), endothelial cell counting, anterior chamber depth(ACD), arch height and postoperative complications. RESULTS: Postoperative UCVA and BCVA improved compared with preoperative, and the difference between preoperative and postoperative was statistically significant(Pt=38.510, 20.100, 34.300; Pt=3.998, 2.837, all Pt=0.383, P>0.05). The corneal endothelium counts in the patients at 3mo and 6mo after surgery were lower than those before surgery(t=2.119, 2.411; all Pt=5.850, 5.260, 2.556; all PCONCLUSION: The new posterior chamber intraocular lens implantation in the treatment of high myopia with low astigmatism reaches satisfaction with less complications, is a good supplement to corneal refractive surgery.